On December 2, the United Nations Commission on narcotic drugs (CND) on Wednesday accepted the World Health Organization (who) proposal to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on narcotic drugs. The proposal was approved by 27 votes in favour, 1 abstention and 25 against. According to the New York Times, the adoption of recommendation 5.1 is conducive to promoting the research and medical application of medical marijuana.
On December 2, the European Commission sent a statement to the European industrial hemp Association, saying that CBD, an extract of industrial hemp, should not be regulated as a drug, but as food. The decision is good for the industrial hemp industry in Europe. CBD processors and manufacturers can sell CBD edible products to the EU market. In addition, CBD was listed in the new food list of EU in January 2019, and relevant CBD food can be sold in the market of 27 EU Member States after being tested and authorized by food safety departments of various countries.
On December 4, the US House of Representatives passed the opportunity reinvestment and deletion act, which legalized cannabis. This is the first time that the US Congress has dealt with the issue of legalizing cannabis at the federal level. In the vote, the Democratic Party had 222 votes for it and six votes against it; the Republican Party had five votes for it and 158 votes against it.
In our opinion, who suggests that the United Nations should delete cannabis and cannabis resin from Schedule IV of the 1961 Convention. The starting point is to recognize the medical use and value of cannabis substances. Overseas multinational policies also reflect the relaxation of medical marijuana and other substances. With the increasing research on CBD and other substances, the health value of CBD is expected to be more discussed and verified. Domestic companies should carry out the business related to industrial hemp within the domestic legal scope, grasp the development opportunities of global industrial hemp related industries, and give full play to the positive role of CBD and other industrial hemp related substances.
At present, industrial hemp has been legalized in Yunnan and Heilongjiang provinces, and some enterprises have made positive progress in the cultivation, processing and application of industrial hemp.
Industrial marijuana is recommended to focus on:
A shares: Fu'an Pharmaceutical (distribution of medical marijuana in the United States), Chenguang biological (a leading plant extraction company with industrial hemp planting and processing license), Kangenbei (with industrial hemp processing license), kunyao group (sales of industrial hemp skin care products), Shunhao shares (layout of industrial hemp industrial chain at home and abroad); Longjin Pharmaceutical (layout of industrial hemp cultivation).
Hong Kong stocks: Meirui Health International (sales of industrial hemp skin care products, comprehensive strategic cooperation with Yunnan Industrial Hemp investment company); xiongan Technology (industrial hemp distributed in the whole industrial chain).